TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy
Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt
Originalsprog | Engelsk |
---|---|
Tidsskrift | European Journal of Cancer |
Vol/bind | 174 |
Udgave nummer | S1 |
Sider (fra-til) | S118 |
ISSN | 0959-8049 |
DOI | |
Status | Udgivet - 2022 |
ID: 340536994